{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-009552","form_type":"8-K","ticker":"MRK","cik":"0000310158","company_name":"Merck & Co., Inc.","filed_at":"2023-02-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.580108+00:00","generated_at":"2026-06-20T02:49:26.372365+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Merck Q4 GAAP EPS $1.18, revenue $13.8B; guides FY2023 non-GAAP EPS $6.80-$6.95","bullets":["Q4 2022 GAAP EPS $1.18 (down 22% YoY); non-GAAP EPS $1.62 (down 10%); revenue $13.8B (+2%, +8% ex-FX).","Full-year 2022 sales $59.3B (+22% YoY); KEYTRUDA $20.9B (+22%); GARDASIL $6.9B (+22%).","FY2023 guidance: sales $57.2B-$58.7B (incl. ~$1B LAGEVRIO); GAAP EPS $5.86-$6.01; non-GAAP EPS $6.80-$6.95.","Completed Imago BioSciences acquisition for $1.35B; new ADC collaboration with Kelun-Biotech.","Regulatory: KEYTRUDA approved for adjuvant NSCLC; positive KEYNOTE-859 (gastric) and KEYNOTE-966 (biliary) data."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-009552","json":"https://secwatch.observer/filing/0001104659-23-009552.json","markdown":"https://secwatch.observer/filing/0001104659-23-009552.md","text":"https://secwatch.observer/filing/0001104659-23-009552.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/310158/000110465923009552/0001104659-23-009552-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/310158/000110465923009552/tm235007d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T02:49:26.372365+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"119e18b4cebc0daddab6c27e1f767b98996c80e4","claim":"Merck & Co., Inc. reported Fourth-Quarter 2022 results: revenue $13.8 Billion, EPS $1.18; $1.62. Guidance initiated.","evidence_excerpt":"Fourth-Quarter 2022 Worldwide Sales Were $13.8 Billion, an Increase of 2% From Fourth Quarter 2021; Growth Excluding the Impact of Foreign Exchange Was 8% - Fourth-Quarter 2022 GAAP EPS From Continuing Operations Was $1.18; Fourth-Quarter 2022 Non-GAAP EPS Was $1.62","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/310158/000110465923009552/0001104659-23-009552-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Fourth-Quarter 2022"},{"label":"Revenue","value":"$13.8 Billion"},{"label":"EPS","value":"$1.18; $1.62"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"ed6e40bf8e8396516d351133a4d7c5368753de6c","claim":"Merck & Co., Inc. reported Full-Year 2022 results: revenue $59.3 Billion, EPS $5.71; $7.48. Guidance initiated.","evidence_excerpt":"Full-Year 2022 Worldwide Sales Were $59.3 Billion, an Increase of 22% From Full Year 2021; Growth Excluding LAGEVRIO Was 12%; Growth Excluding LAGEVRIO and the Impact of Foreign Exchange Was 15% o KEYTRUDA Sales Grew 22% to $20.9 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 27% o GARDASIL/GARDASIL 9 Sales Grew 22% to $6.9 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 27% - Full-Year 2022 GAAP EPS From Continuing Operations Was $5.71; Full-Year 2022 Non-GAAP EPS Was $7.48","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/310158/000110465923009552/0001104659-23-009552-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full-Year 2022"},{"label":"Revenue","value":"$59.3 Billion"},{"label":"EPS","value":"$5.71; $7.48"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}